Regulus Therapeutics Company Profile (NASDAQ:RGLS)

About Regulus Therapeutics

Regulus Therapeutics logoRegulus Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs to treat a range of diseases. The Company uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs to modulate microRNAs and return diseased cells to their healthy state. The Company's Regulus microMarkers division is focused on identifying microRNAs as biomarkers of human disease. It has a research collaboration with Biogen focused on the discovery of microRNAs as biomarkers for multiple sclerosis and has completed research for another pharmaceutical company to explore microRNAs as biomarkers for specific patient populations. The Company is developing RG-101, an N-Acetylgalactosamine (GalNAc)-conjugated anti-miR targeting miR-122; RG-012, an anti-miR targeting microRNA-21 for the treatment of Alport syndrome, and RG-125, a GalNAc-conjugated anti-miR targeting microRNA-103/107.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: RGLS
  • CUSIP: 75915K10
Key Metrics:
  • Previous Close: $1.05
  • 50 Day Moving Average: $1.73
  • 200 Day Moving Average: $2.64
  • 52-Week Range: $0.94 - $8.90
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -0.78
  • P/E Growth: -0.02
  • Market Cap: $55.57M
  • Outstanding Shares: 52,923,000
  • Beta: 1.81
Profitability:
  • Net Margins: -573.63%
  • Return on Equity: -70.38%
  • Return on Assets: -53.58%
Debt:
  • Debt-to-Equity Ratio: 0.27%
  • Current Ratio: 7.82%
  • Quick Ratio: 7.82%
Additional Links:
Companies Related to Regulus Therapeutics:

Analyst Ratings

Consensus Ratings for Regulus Therapeutics (NASDAQ:RGLS) (?)
Ratings Breakdown: 4 Hold Ratings, 4 Buy Ratings
Consensus Rating:Buy (Score: 2.50)
Consensus Price Target: $7.67 (630.16% upside)

Analysts' Ratings History for Regulus Therapeutics (NASDAQ:RGLS)
Show:
DateFirmActionRatingPrice TargetDetails
2/8/2017WedbushReiterated RatingOutperform$8.00View Rating Details
1/30/2017Needham & Company LLCDowngradeBuy -> HoldView Rating Details
1/30/2017Wells Fargo & CoDowngradeOutperform -> Market PerformView Rating Details
12/16/2016Cantor FitzgeraldInitiated CoverageOverweight$11.00View Rating Details
12/7/2016Chardan CapitalLower Price TargetBuy$12.00 -> $5.00View Rating Details
11/2/2016Cowen and CompanyDowngradeOutperform -> Market PerformView Rating Details
6/28/2016FBR & CoReiterated RatingOutperform$30.00 -> $9.00View Rating Details
6/28/2016BMO Capital MarketsDowngradeOutperform -> Market Perform$16.00 -> $4.00View Rating Details
6/8/2015GuggenheimInitiated CoverageBuy$16.00View Rating Details
6/2/2015Deutsche Bank AGSet Price TargetBuy$27.00View Rating Details
(Data available from 2/27/2015 forward)

Earnings

Earnings History for Regulus Therapeutics (NASDAQ:RGLS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/2/2017        
8/2/2016Q216($0.38)($0.40)$2.49 millionViewListenView Earnings Details
5/2/2016Q1($0.33)($0.40)ViewListenView Earnings Details
2/22/2016Q415($0.25)($0.14)$5.09 million$10.90 millionViewListenView Earnings Details
11/5/2015Q315($0.37)($0.25)$2.85 millionViewN/AView Earnings Details
8/4/2015Q215($0.29)($0.41)$2.40 million$3.80 millionViewN/AView Earnings Details
5/7/2015($0.26)($0.25)ViewListenView Earnings Details
2/18/2015($0.21)($0.47)ViewListenView Earnings Details
11/5/2014($0.23)($0.23)ViewListenView Earnings Details
8/6/2014Q214($0.19)($0.29)$3.19 millionViewN/AView Earnings Details
5/8/2014($0.14)($0.30)ViewN/AView Earnings Details
2/27/2014($0.13)($0.11)ViewN/AView Earnings Details
8/13/20132Q13($0.14)($0.20)$3.44 million$4.80 millionViewN/AView Earnings Details
2/20/2013Q412($0.08)($0.22)$3.50 million$3.24 millionViewN/AView Earnings Details
11/19/2012Q312($15.98)$3.81 million$2.80 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Regulus Therapeutics (NASDAQ:RGLS)
Current Year EPS Consensus Estimate: $-1.49 EPS
Next Year EPS Consensus Estimate: $-1.35 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162($0.33)($0.32)($0.33)
Q2 20162($0.42)($0.32)($0.37)
Q3 20162($0.44)($0.36)($0.40)
Q4 20162($0.39)($0.34)($0.37)
Q1 20171($0.35)($0.35)($0.35)
Q2 20171($0.35)($0.35)($0.35)
Q3 20171($0.35)($0.35)($0.35)
Q4 20171($0.35)($0.35)($0.35)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Regulus Therapeutics (NASDAQ:RGLS)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Regulus Therapeutics (NASDAQ:RGLS)
Insider Ownership Percentage: 2.30%
Institutional Ownership Percentage: 50.10%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
3/3/2016Joseph P HaganCOOBuy10,000$7.19$71,900.00View SEC Filing  
2/23/2016Alnylam Pharmaceuticals, Inc.Major ShareholderSell1,000,000$7.18$7,180,000.00View SEC Filing  
7/21/2015William H RastetterDirectorBuy100,000$10.17$1,017,000.00View SEC Filing  
7/20/2015William H RastetterDirectorBuy38,765$10.13$392,689.45View SEC Filing  
7/17/2015Isis Pharmaceuticals IncMajor ShareholderSell343,133$10.60$3,637,209.80View SEC Filing  
4/21/2015Kleanthis G XanthopoulosCEOSell200,000$17.15$3,430,000.00View SEC Filing  
4/13/2015Bruce L A CarterDirectorSell20,000$17.66$353,200.00View SEC Filing  
3/5/2015Kleanthis G XanthopoulosCEOSell89,230$20.26$1,807,799.80View SEC Filing  
2/2/2015Kleanthis G XanthopoulosCEOSell5,700$19.61$111,777.00View SEC Filing  
1/29/2015Kleanthis G XanthopoulosCEOSell145,000$18.06$2,618,700.00View SEC Filing  
1/28/2015Neil W GibsonInsiderSell80,000$18.05$1,444,000.00View SEC Filing  
11/28/2014Neil W GibsonInsiderSell2,500$19.30$48,250.00View SEC Filing  
11/3/2014Isis Pharmaceuticals IncMajor ShareholderSell1,279,411$15.94$20,393,811.34View SEC Filing  
10/24/2014Alnylam Pharmaceuticals, Inc.Major ShareholderSell113,084$14.02$1,585,437.68View SEC Filing  
10/22/2014Neil W GibsonInsiderSell3,300$14.44$47,652.00View SEC Filing  
10/10/2014Alnylam Pharmaceuticals, Inc.Major ShareholderSell2,000$6.41$12,820.00View SEC Filing  
10/10/2014Isis Pharmaceuticals IncDirectorSell10,050$6.56$65,928.00View SEC Filing  
10/9/2014Isis Pharmaceuticals IncDirectorSell4,750$6.58$31,255.00View SEC Filing  
10/8/2014Isis Pharmaceuticals IncDirectorSell3,300$6.63$21,879.00View SEC Filing  
10/3/2014Alnylam Pharmaceuticals, Inc.Major ShareholderSell10,300$6.74$69,422.00View SEC Filing  
10/3/2014Isis Pharmaceuticals IncDirectorSell3,300$6.88$22,704.00View SEC Filing  
10/2/2014Isis Pharmaceuticals IncDirectorSell3,750$6.64$24,900.00View SEC Filing  
10/1/2014Isis Pharmaceuticals IncDirectorSell3,250$6.71$21,807.50View SEC Filing  
9/30/2014Kleanthis G XanthopoulosCEOSell2,300$7.02$16,146.00View SEC Filing  
9/26/2014Alnylam Pharmaceuticals, Inc.Major ShareholderSell2,500$7.04$17,600.00View SEC Filing  
9/26/2014Isis Pharmaceuticals IncDirectorSell8,750$7.13$62,387.50View SEC Filing  
9/25/2014Alnylam Pharmaceuticals, Inc.Major ShareholderSell2,500$7.12$17,800.00View SEC Filing  
9/24/2014Alnylam Pharmaceuticals, Inc.Major ShareholderSell3,750$7.19$26,962.50View SEC Filing  
9/19/2014Alnylam Pharmaceuticals, Inc.Major ShareholderSell7,700$7.31$56,287.00View SEC Filing  
9/19/2014Isis Pharmaceuticals IncDirectorSell4,100$7.22$29,602.00View SEC Filing  
9/18/2014Isis Pharmaceuticals IncDirectorSell1,500$7.40$11,100.00View SEC Filing  
9/17/2014Isis Pharmaceuticals IncDirectorSell2,100$7.43$15,603.00View SEC Filing  
9/12/2014Alnylam Pharmaceuticals, Inc.Major ShareholderSell8,900$7.85$69,865.00View SEC Filing  
9/12/2014Isis Pharmaceuticals IncDirectorSell3,500$7.96$27,860.00View SEC Filing  
9/12/2014Neil W GibsonInsiderSell4,200$8.01$33,642.00View SEC Filing  
9/11/2014Isis Pharmaceuticals IncDirectorSell3,400$7.83$26,622.00View SEC Filing  
9/10/2014Isis Pharmaceuticals IncDirectorSell2,000$7.70$15,400.00View SEC Filing  
9/5/2014Isis Pharmaceuticals IncDirectorSell10,050$7.07$71,053.50View SEC Filing  
8/29/2014Isis Pharmaceuticals IncDirectorSell1,500$6.84$10,260.00View SEC Filing  
8/28/2014Isis Pharmaceuticals IncDirectorSell2,000$6.96$13,920.00View SEC Filing  
8/28/2014Kleanthis G XanthopoulosCEOSell3,505$7.06$24,745.30View SEC Filing  
8/27/2014Isis Pharmaceuticals IncDirectorSell1,500$7.21$10,815.00View SEC Filing  
8/22/2014Alnylam Pharmaceuticals, Inc.Major ShareholderSell5,250$6.75$35,437.50View SEC Filing  
8/21/2014Alnylam Pharmaceuticals, Inc.Major ShareholderSell2,500$6.89$17,225.00View SEC Filing  
8/20/2014Alnylam Pharmaceuticals, Inc.Major ShareholderSell3,000$7.14$21,420.00View SEC Filing  
8/15/2014Alnylam Pharmaceuticals, Inc.Major ShareholderSell1,450$6.98$10,121.00View SEC Filing  
8/14/2014Alnylam Pharmaceuticals, Inc.Major ShareholderSell1,750$7.04$12,320.00View SEC Filing  
8/13/2014Alnylam Pharmaceuticals, Inc.Major ShareholderSell2,250$7.02$15,795.00View SEC Filing  
8/8/2014Isis Pharmaceuticals IncDirectorSell1,850$6.80$12,580.00View SEC Filing  
8/7/2014Isis Pharmaceuticals IncDirectorSell2,600$6.66$17,316.00View SEC Filing  
8/6/2014Isis Pharmaceuticals IncDirectorSell3,150$7.08$22,302.00View SEC Filing  
8/1/2014Isis Pharmaceuticals IncDirectorSell2,600$6.21$16,146.00View SEC Filing  
7/31/2014Isis Pharmaceuticals IncDirectorSell1,750$6.42$11,235.00View SEC Filing  
7/30/2014Isis Pharmaceuticals IncDirectorSell1,000$6.60$6,600.00View SEC Filing  
7/25/2014Isis Pharmaceuticals IncDirectorSell1,700$6.55$11,135.00View SEC Filing  
7/24/2014Isis Pharmaceuticals IncDirectorSell1,850$6.81$12,598.50View SEC Filing  
7/23/2014Isis Pharmaceuticals IncDirectorSell1,700$6.88$11,696.00View SEC Filing  
7/18/2014Isis Pharmaceuticals IncDirectorSell5,000$6.80$34,000.00View SEC Filing  
7/17/2014Isis Pharmaceuticals IncDirectorSell5,000$6.58$32,900.00View SEC Filing  
7/16/2014Isis Pharmaceuticals IncDirectorSell3,500$6.59$23,065.00View SEC Filing  
7/11/2014Isis Pharmaceuticals IncDirectorSell1,750$6.48$11,340.00View SEC Filing  
7/10/2014Isis Pharmaceuticals IncDirectorSell4,500$6.69$30,105.00View SEC Filing  
7/9/2014Isis Pharmaceuticals IncDirectorSell1,800$7.08$12,744.00View SEC Filing  
2/4/2014Sanofimajor shareholderBuy1,303,780$7.67$9,999,992.60View SEC Filing  
1/21/2014Neil GibsonInsiderSell4,421$8.09$35,765.89View SEC Filing  
1/17/2014Neil GibsonInsiderSell4,479$8.15$36,503.85View SEC Filing  
1/16/2014Neil GibsonInsiderSell1,100$8.03$8,833.00View SEC Filing  
1/2/2014Kleanthis XanthopoulosCEOSell3,505$7.25$25,411.25View SEC Filing  
10/10/2012Stanley T CrookeDirectorBuy750,000$4.00$3,000,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Regulus Therapeutics (NASDAQ:RGLS)
DateHeadline
News IconSell-side Consensus Sees Regulus Therapeutics Inc. (NASDAQ:RGLS) Going Where Near-Term? - Aiken Advocate (NASDAQ:RGLS)
aikenadvocate.com - February 27 at 4:21 PM
finance.yahoo.com logoIMPORTANT EQUITY NOTICE: Lundin Law PC Announces Securities Class Action Lawsuit against Regulus ... - Yahoo Finance (NASDAQ:RGLS)
finance.yahoo.com - February 27 at 4:21 PM
finance.yahoo.com logoIMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against ... - Yahoo Finance (NASDAQ:RGLS)
finance.yahoo.com - February 27 at 4:21 PM
globenewswire.com logoRGLS INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Regulus ... - GlobeNewswire (press release) (NASDAQ:RGLS)
globenewswire.com - February 27 at 4:21 PM
News IconCompany Shares of Regulus Therapeutics Inc. (RGLS) Drops by -4.35% - Highland Mirror (NASDAQ:RGLS)
www.highlandmirror.com - February 27 at 4:21 PM
feeds.benzinga.com logoRGLS INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Regulus Therapeutics Inc. and a Lead Plaintiff Deadline of April 3, 2017 (NASDAQ:RGLS)
feeds.benzinga.com - February 27 at 12:52 PM
einnews.com logoThe Latest: Kurt Busch wins Daytona 500 for Stewart-Haas (NASDAQ:RGLS)
semiconductors.einnews.com - February 27 at 9:32 AM
einnews.com logoFormer Australian of the Year finalist Eman Sharobeem exits boards, SBS amid fraud investigation (NASDAQ:RGLS)
it.einnews.com - February 27 at 9:32 AM
einnews.com logoOscars 2017: First Muslim actor Mahershala Ali wins Oscar for best supporting actor for Moonlight, see pics (NASDAQ:RGLS)
ethanol.einnews.com - February 27 at 9:32 AM
openpr.com logoRegulus Therapeutics Inc (NASDAQ:RGLS) Investor Lawsuit alleges Misleading Statements (NASDAQ:RGLS)
www.openpr.com - February 27 at 9:32 AM
einnews.com logo16 killed, 50 injured as truck overturns in India (NASDAQ:RGLS)
semiconductors.einnews.com - February 26 at 6:35 PM
einnews.com logoJade Jones eliminated from The Jump 2017 but 'still in one piece!' (NASDAQ:RGLS)
ethanol.einnews.com - February 26 at 6:35 PM
einnews.com logo6 bull riders, 2 companions reported kidnapped in Mexico (NASDAQ:RGLS)
it.einnews.com - February 26 at 6:35 PM
realistinvestor.com logoRegulus Therapeutics Inc. (NASDAQ:RGLS) EPS Projection At $-0.36 - RealistInvestor.com (NASDAQ:RGLS)
www.realistinvestor.com - February 26 at 11:45 AM
finance.yahoo.com logoSHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Regulus Therapeutics Inc. (RGLS) To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit (NASDAQ:RGLS)
finance.yahoo.com - February 26 at 11:45 AM
News IconRegulus Therapeutics Inc RGLS Financial and Strategic SWOT Analysis Review [Updated: 13012017] Prices from USD $300 (NASDAQ:RGLS)
www.bioportfolio.com - February 24 at 9:01 PM
finance.yahoo.com logoRegulus to Release Fourth Quarter and Full Year 2016 Financial Results on March 2, 2017 (NASDAQ:RGLS)
finance.yahoo.com - February 23 at 7:40 PM
finance.yahoo.com logoIMPORTANT INVESTOR NOTICE: Lundin Law PC Announces Securities Class Action Lawsuit against Regulus Therapeutics Inc. and Encourages Investors with Losses to Contact the Firm (NASDAQ:RGLS)
finance.yahoo.com - February 22 at 9:34 AM
us.rd.yahoo.com logoSHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Regulus Therapeutics Inc. (RGLS) and Lead Plaintiff Deadline: April 3, 2017 (NASDAQ:RGLS)
us.rd.yahoo.com - February 21 at 5:20 PM
feeds.benzinga.com logoINVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders It Has Commenced a Class Action on Behalf of Shareholders of Regulus Therapeutics Inc. –Lead Plaintiff Deadline of April 3, 2017 (NASDAQ:RGLS)
feeds.benzinga.com - February 21 at 12:45 PM
News IconWhat is the Street Saying About Regulus Therapeutics Inc. (NASDAQ:RGLS)? - Aiken Advocate (NASDAQ:RGLS)
aikenadvocate.com - February 20 at 6:44 PM
benzinga.com logoSHAREHOLDER ALERT: Pomerantz Law Firm Reminds... (NASDAQ:RGLS)
www.benzinga.com - February 18 at 6:37 PM
News IconNASDAQ:RGLS Investor Notice: Lawsuit alleges Misleading Statements by Regulus Therapeutics Inc (NASDAQ:RGLS)
www.groundreport.com - February 18 at 6:37 PM
globenewswire.com logoSHAREHOLDER ALERT: Pomerantz Law Firm Reminds ... - GlobeNewswire (press release) (NASDAQ:RGLS)
globenewswire.com - February 18 at 8:19 AM
feeds.benzinga.com logoSHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Regulus Therapeutics Inc. of Class Action Lawsuit and Upcoming Deadline – RGLS (NASDAQ:RGLS)
feeds.benzinga.com - February 17 at 9:51 PM
4-traders.com logoREGULUS THERAPEUTICS INC : Khang & Khang LLP Announces Securities Class Action.. (NASDAQ:RGLS)
www.4-traders.com - February 17 at 7:54 PM
streetinsider.com logoRegulus (RGLS) Announces Publication of Article Identifying miR-17 as Promising Drug Target for ADPKD (NASDAQ:RGLS)
www.streetinsider.com - February 16 at 7:11 PM
us.rd.yahoo.com logoSHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Regulus Therapeutics Inc. (RGLS) and Lead Plaintiff Deadline: April 3, 2017 (NASDAQ:RGLS)
us.rd.yahoo.com - February 16 at 7:11 PM
us.rd.yahoo.com logoSHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Regulus Therapeutics Inc. (RGLS) and Lead Plaintiff Deadline: April 3, 2017 (NASDAQ:RGLS)
us.rd.yahoo.com - February 16 at 7:11 PM
finance.yahoo.com logoRegulus Announces Publication in Nature Communications Identifying miR-17 as a Promising Drug Target for ADPKD (NASDAQ:RGLS)
finance.yahoo.com - February 16 at 7:11 PM
finance.yahoo.com logo8:32 am Regulus Therapeutics announces that Nature Communications has published an article entitled 'microRNA-17 family promotes polycystic kidney disease progression through the modulation of mitochondrial metabolism' identifying miR-17 as (NASDAQ:RGLS)
finance.yahoo.com - February 16 at 7:11 PM
us.rd.yahoo.com logoEXPANDED CLASS PERIOD: Levi & Korsinsky, LLP Files in U.S. District Court to Recover Losses Suffered by Investors in Regulus Therapeutics Inc. -Lead Plaintiff Deadline of April 3, 2017 (NASDAQ:RGLS)
us.rd.yahoo.com - February 15 at 12:49 AM
us.rd.yahoo.com logoIMPORTANT EQUITY ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Regulus Therapeutics Inc. and Encourages Investors with Losses to Contact the Firm (NASDAQ:RGLS)
us.rd.yahoo.com - February 15 at 12:49 AM
News IconWhat are Research Firms Saying About Regulus Therapeutics Inc. (NASDAQ:RGLS)? - Aiken Advocate (NASDAQ:RGLS)
aikenadvocate.com - February 14 at 5:37 AM
finance.yahoo.com logoIMPORTANT EQUITY ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Regulus Therapeutics Inc. and Encourages Investors with Losses to Contact the Firm (NASDAQ:RGLS)
finance.yahoo.com - February 14 at 5:37 AM
us.rd.yahoo.com logoINVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Regulus Therapeutics Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of April 3, 2017 – RGLS (NASDAQ:RGLS)
us.rd.yahoo.com - February 11 at 3:36 AM
News IconTrading Monitor: Watching Shares of Regulus Therapeutics Inc. (RGLS) - Davidson Register (NASDAQ:RGLS)
davidsonregister.com - February 10 at 10:35 PM
finance.yahoo.com logoSHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Regulus Therapeutics Inc. of Class Action Lawsuit and Upcoming Deadline - RGLS (NASDAQ:RGLS)
finance.yahoo.com - February 10 at 10:35 PM
finance.yahoo.com logoIMPORTANT REGULUS THERAPEUTICS INC. INVESTOR ALERT: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed in the Southern District of California against Regulus Therapeutics Inc. (NASDAQ:RGLS)
finance.yahoo.com - February 9 at 11:12 PM
finance.yahoo.com logoIMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Regulus Therapeutics Inc. and Encourages Investors with Losses to Contact the Firm (NASDAQ:RGLS)
finance.yahoo.com - February 9 at 11:12 PM
finance.yahoo.com logoRGLS INVESTOR ALERT: Goldberg Law PC Announces Securities Class Action Lawsuit against Regulus Therapeutics Inc. and Encourages Investors with Losses to Contact the Firm (NASDAQ:RGLS)
finance.yahoo.com - February 8 at 11:07 PM
finance.yahoo.com logoINVESTOR ALERT: Brower Piven Encourages Shareholders Who Have Losses In Excess Of $100,000 From Investment In Regulus Therapeutics Inc. To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit (NASDAQ:RGLS)
finance.yahoo.com - February 8 at 11:06 PM
finance.yahoo.com logoIMPORTANT SHAREHOLDER ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Regulus Therapeutics Inc. and Encourages Investors with Losses to Contact the Firm (NASDAQ:RGLS)
finance.yahoo.com - February 8 at 11:06 PM
finance.yahoo.com logoRegulus to Present at Upcoming Healthcare Conferences (NASDAQ:RGLS)
finance.yahoo.com - February 8 at 11:06 PM
tmcnet.com logoIMPORTANT INVESTOR ALERT: Khang & Khang LLP Announces Securities … (NASDAQ:RGLS)
www.tmcnet.com - February 6 at 7:37 PM
News IconLawsuit for Investors in Shares of Regulus Therapeutics Inc (NASDAQ:RGLS) in Effort to Recover Losses Filed (NASDAQ:RGLS)
www.digitaljournal.com - February 6 at 7:37 PM
finance.yahoo.com logoIMPORTANT INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Regulus Therapeutics Inc. and Encourages Investors with Losses to Contact the Firm (NASDAQ:RGLS)
finance.yahoo.com - February 6 at 7:37 PM
feeds.benzinga.com logoRGLS SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notifies Investors of a Class Action Involving Regulus Therapeutics Inc. and a Lead Plaintiff Deadline of April 3, 2017 (NASDAQ:RGLS)
feeds.benzinga.com - February 6 at 12:24 PM
News IconRegulus Therapeutics Inc RGLS Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250 (NASDAQ:RGLS)
www.bioportfolio.com - February 6 at 8:46 AM
tmcnet.com logoIMPORTANT INVESTOR ALERT: Lundin Law PC Announces Securities … (NASDAQ:RGLS)
www.tmcnet.com - February 4 at 3:49 AM

Social

What is Regulus Therapeutics' stock symbol?

Regulus Therapeutics trades on the NASDAQ under the ticker symbol "RGLS."

Where is Regulus Therapeutics' stock going? Where will Regulus Therapeutics' stock price be in 2017?

8 brokerages have issued 1 year target prices for Regulus Therapeutics' shares. Their predictions range from $4.00 to $11.00. On average, they expect Regulus Therapeutics' stock price to reach $7.67 in the next year.

When will Regulus Therapeutics announce their earnings?

Regulus Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, March, 2nd 2017.

What are analysts saying about Regulus Therapeutics stock?

Here are some recent quotes from research analysts about Regulus Therapeutics stock:

  • Needham & Company LLC analysts commented, "RGLS announced late Friday that FDA has extended RG-101 clinical hold and requested additional long-term clinical data from ongoing trials. These data are not expected until 4Q17. We've removed the program from our model considering extensive development risk. Regardless, opportunity for RGLS to capture value in HCV is fading in our view given growing number of effective once-daily oral options. Though we believe microRNA platform has substantial potential, we are downgrading to HOLD due to absence of near-term material clinical milestones. A key value-creating milestone in our view is top-line results from Phase 2 proof-of-concept trial of RG-012 in Alport Syndrome. This trial is expected to begin mid-2017, with results available in 2018. Data from RG-125 Phase 2 trial in NAFLD (collaborator AstraZeneca) are expected 3Q17." (1/30/2017)
  • According to Zacks Investment Research, "Regulus Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs, called microRNA therapeutics. The Company's products aim to treat or prevent hepatitis C infections, cardiovascular disease, fibrosis, oncology, immuno-inflammatory diseases, and metabolic diseases. Regulus Therapeutics Inc. is based in La Jolla, California. " (1/19/2017)

Who owns Regulus Therapeutics stock?

Regulus Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional investors include FMR LLC (15.00%), State Street Corp (1.04%), Renaissance Technologies LLC (0.61%), A.R.T. Advisors LLC (0.17%) and Tudor Investment Corp Et Al (0.09%). Company insiders that own Regulus Therapeutics stock include Alnylam Pharmaceuticals, Inc, Bruce L A Carter, Isis Pharmaceuticals Inc, Joseph P Hagan, Kleanthis G Xanthopoulos and William H Rastetter.

Who sold Regulus Therapeutics stock? Who is selling Regulus Therapeutics stock?

Regulus Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC and State Street Corp.

Who bought Regulus Therapeutics stock? Who is buying Regulus Therapeutics stock?

Regulus Therapeutics' stock was bought by a variety of institutional investors in the last quarter, including A.R.T. Advisors LLC, Tudor Investment Corp Et Al and FMR LLC. Company insiders that have bought Regulus Therapeutics stock in the last two years include Joseph P Hagan and William H Rastetter.

How do I buy Regulus Therapeutics stock?

Shares of Regulus Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Regulus Therapeutics stock cost?

One share of Regulus Therapeutics stock can currently be purchased for approximately $1.05.

Regulus Therapeutics (NASDAQ:RGLS) Chart for Monday, February, 27, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Regulus Therapeutics (NASDAQ:RGLS)

Earnings History Chart

Earnings by Quarter for Regulus Therapeutics (NASDAQ:RGLS)

Dividend History Chart

Dividend Payments by Quarter for Regulus Therapeutics (NASDAQ:RGLS)

Last Updated on 2/27/2017 by MarketBeat.com Staff